LncRNA GAS5 contributes to lymphatic metastasis in colorectal cancer

Yongbin Zheng1, Dan Song1, Kuang Xiao1, Cao Yang1, Yu Ding1, Wenhong Deng1, Shilun Tong1

1Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, PR China

Correspondence to: Yongbin Zheng. email: zhengyongbinhb@163.com

Keywords: colorectal cancer, GAS5, metastasis, LncRNA

Received: August 17, 2016 Accepted: October 19, 2016 Published: November 16, 2016

ABSTRACT

Colorectal cancer (CRC) ranks the third most common type of cancer worldwide. However, the detailed molecular mechanisms underlying these processes are poorly understood. Recent studies have shown that lncRNAs play important roles in carcinogenesis and progression of CRC. The lncRNA growth arrest special 5 (GAS5), was previously identified to be down-regulated and functions as a tumor suppressor gene in many kinds of cancers. In current two-stage, case-control study, we systematically evaluated the potential role of lncRNA GAS5 and its genetic variation rs145204276 in the development and metastasis process of CRC in a Chinese population. We found the allele del of rs145204276 was significantly associated with 21% decreased risk of CRC (OR=0.79; 95% CI=0.70-0.89; P value = 5.21×10^-5). Compared with the genotype ins/ins, both the genotype ins/del (OR=0.78; 95% CI=0.68-0.91) and del/del (OR=0.64; 95% CI=0.49-0.84) showed decreased susceptibility. For both in colon and rectum cancers, the associations kept statistically significant (OR=0.78 and 0.80, while P value = 4.56×10^-4, and 3.80×10^-3, respectively). The results also showed that the carriers of allele del are less likely to get lymph node metastasis (OR=0.80; 95% CI=0.68-0.95; P value = 0.010). Taken together, our findings provided strong evidence for the hypothesis that GAS5 rs145204276 were significantly associated with the susceptibility and progression of CRC.

INTRODUCTION

Colorectal cancer (CRC) remains one of the leading cause of cancer-related death and the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4 million cases and 693,900 deaths occurring in 2012 worldwide [1, 2]. In United States, the estimated new CRC cases and deaths were 134,490 and 49,190 respectively in 2016 [3]. While in China, the estimated new cancer cases and deaths were 376.3 and 191.0 thousands respectively, according to the Chinese National Office for Cancer Prevention and Control [4]. About 11.0% of CRC patients had synchronous lung metastases, which caused that the 3-year relative survival rate was 11.3% [5]. All evidence above suggest that CRC is still a big threat to human health and public health problem. Although some genetic factors, body weight, physically activity, consumption of red and processed meat and alcohol, and smoking has been identified to be associated with the outcomes of CRC patients, relapse and metastasis happened in many CRC patients, however, the detailed molecular mechanisms underlying these processes are poorly understood [6-8].

Increasing evidence shows that long noncoding RNAs (IncRNAs) are involved in all aspects of cellular physiology critical for cancer initiation, progression, and metastasis [9-23]. The IncRNA growth arrest special 5 (GAS5), which was located at 1q25, was identified to be down-regulated and functions as a tumor suppressor gene in many kinds of cancers, including breast cancer, prostate cancer, pancreatic cancer, bladder cancer, lung cancer, gastric cancer, and so on [24-31]. Tao et al [32] also identified that the deletion allele of a 5-base pair indel polymorphism (rs145204276) in the promotor region of GAS5 significantly increased the risk of hepatocellular carcinoma (HCC) and increased the expression of GAS5...
in hepatocellular cell lines, which indicated the differential roles of GAS5 in carcinogenesis of different cancer types. In current study, we aim to systematically evaluate the potential role of IncRNA GAS5 and its genetic variation rs145204276 in the development and metastasis process of CRC in a Chinese population.

RESULTS

Population characteristics

As shown in Table 1, characteristics of the subjects included in the two stage of current study were generally comparable. No significant difference were detected for age group, gender, alcohol status and smoking status between CRC cases and healthy controls (all the P value > 0.05). Table 1 also present the percentages of different tumor sites (Colon and Rectum), lymph node metastasis and distant metastasis, which are similar between the two stages in current study. The distribution of genotypes of rs145204276 in healthy controls in the two stage was in accordance with Hardy-Weinberg equilibrium (HWE, P > 0.05).

Associations between GAS5 rs145204276 and CRC susceptibility

Table 2 presents the association between GAS5 rs145204276 and CRC susceptibility in two independent stages. In stage I, the allele del was significantly associated with decreased risk of CRC (OR=0.81; 95% CI=0.68-0.96; P value = 0.016). Thus, we replicated the association in an independent stage (stage II), which also presented a significant association (OR=0.78; 95% CI=0.67-0.91; P value = 1.24×10^-3). When pooled together, the allele del was significantly associated with 21% decreased risk of CRC (OR=0.79; 95% CI=0.70-0.89; P value = 5.21×10^-3). Compared with the genotype ins/ins, both subjects with the genotype ins/del (OR=0.86; 95% CI=0.68-1.08) and genotype del/del (OR=0.58; 95% CI=0.37-0.90) showed decreased possibility of lymph node metastasis. Due to limited the sample size and statistical power, the association between GAS5 rs145204276 and distant metastasis of CRC was marginal significant (OR=0.80; 95% CI=0.63-1.02; P value = 0.07).

Relative expression of GAS5

we also examined expression level of GAS5 in CRC tumor tissues and adjacent normal tissues of 50 CRC cases (Figure 1). Among all the pairs of CRC patients, the expression levels of IncRNA GAS5 in CRC tissues were significantly lower than those in the corresponding normal tissues (P<0.001).

DISCUSSION

In this two-stage, case-control study with large sample size, we systematically evaluated the association of GAS5 rs145204276 with the susceptibility and progression of CRC among Chinese population. We found the allele del of rs145204276 was significantly associated with 21% decreased risk of CRC (OR=0.79; 95% CI=0.70-0.89; P value = 5.21×10^-3). The associations kept statistically significant in colon and rectum cancers, and the results also showed that the carriers of allele del are less likely to get lymph node metastasis. To the best of our knowledge, this should be first study which systematically evaluated the genetic association of GAS5 with the susceptibility and progression of CRC.

LncRNAs have been identified to be involved in multiple biological functions, and also plays a vital role in CRC carcinogenesis [15, 33-48]. Some LncRNAs are related to the poor prognosis of CRC [39, 42, 44, 45], while some others are associated with occurrence of CRC [33, 37, 43, 47]. Han et al [48] also found that 14 LncRNAs were specifically up-regulated and 5 specifically down-regulated in metastatic lymph node of CRC patients, compared with those of normal lymph node. Recently, Chen et al [34] identified that 2636 LncRNAs, including 1600 up-regulated and 1036 down-regulated over two-fold compared with the CRC tissues without metastasis, were associated with liver metastasis of CRC through a genome-wide analysis of IncRNA expression. All studies above provide solid evidence that LncRNAs play essential role in the development and metastasis process of CRC.

The GAS5 gene, which was first reported by Coccia et al in 1992, was isolated from mouse genomic DNA and structurally characterized [49]. The transcriptional unit is
Table 1: The characteristics of the study population

| Variables               | Stage I                  | Stage II                  | P value | Stage I                  | Stage II                  | P value |
|-------------------------|--------------------------|---------------------------|---------|--------------------------|---------------------------|---------|
|                         | Cases (n=600)            | Controls (n=600)          |         | Cases (n=800)            | Controls (n=800)          |         |
| Age group               |                          |                           |         |                          |                           |         |
| ≥60                     | 255 (42.5%)              | 264 (44.0%)               | 0.600   | 365 (45.6%)              | 362 (45.2%)               | 0.880   |
| <60                     | 345 (57.5%)              | 336 (56.0%)               |         | 435 (54.4%)              | 438 (54.8%)               |         |
| Gender                  |                          |                           |         |                          |                           |         |
| Male                    | 369 (61.5%)              | 372 (62.0%)               | 0.859   | 480 (60.0%)              | 468 (58.5%)               | 0.542   |
| female                  | 231 (38.5%)              | 228 (38.0%)               |         | 320 (40.0%)              | 332 (41.5%)               |         |
| Smoking status          |                          |                           |         |                          |                           |         |
| Smokers                 | 186 (31.0%)              | 171 (28.5%)               | 0.344   | 232 (29.0%)              | 212 (26.5%)               | 0.264   |
| Non-Smokers             | 414 (69.0%)              | 429 (71.5%)               |         | 568 (71.0%)              | 588 (73.5%)               |         |
| Alcohol status          |                          |                           |         |                          |                           |         |
| drinkers                | 201 (33.5%)              | 180 (30.0%)               | 0.193   | 280 (35.0%)              | 256 (32.0%)               | 0.204   |
| Non-drinkers            | 399 (66.5%)              | 420 (70.0%)               |         | 520 (65.0%)              | 544 (68.0%)               |         |
| Tumor site              |                          |                           |         |                          |                           |         |
| Colon                   | 340 (56.7%)              |                           |         | 466 (58.2%)              |                           |         |
| Rectum                  | 260 (43.3%)              |                           |         | 334 (41.8%)              |                           |         |
| Lymph node metastasis   |                          |                           |         |                          |                           |         |
| No                      | 390 (65.0%)              |                           |         | 500 (62.5%)              |                           |         |
| Yes                     | 210 (35.0%)              |                           |         | 300 (37.5%)              |                           |         |
| Distant metastasis      |                          |                           |         |                          |                           |         |
| No                      | 507 (84.5%)              |                           |         | 688 (86.0%)              |                           |         |
| Yes                     | 93 (15.5%)               |                           |         | 112 (14.0%)              |                           |         |

Table 2: Associations between GAS5 rs145204276 and CRC susceptibility among Chinese population

| Genotypes   | Cases (n, %) | Controls (n, %) | OR (95% CI)a | P trend |
|-------------|--------------|-----------------|--------------|---------|
| Stage I     |              |                 |              |         |
| ins/ins     | 320 (53.3%)  | 279 (46.5%)     | 1.00 (Reference) |         |
| ins/del     | 230 (38.3%)  | 258 (43.0%)     | 0.78 (0.61-0.99) |         |
| del/del     | 50 (8.4%)    | 63 (10.5%)      | 0.69 (0.46-1.03) |         |
| del vs ins  |              |                 | 0.81 (0.68-0.96) | 0.016   |
| Stage II    |              |                 |              |         |
| ins/ins     | 418 (52.3%)  | 360 (45.0%)     | 1.00 (Reference) |         |
| ins/del     | 320 (40.0%)  | 352 (44.0%)     | 0.78 (0.64-0.96) |         |
| del/del     | 62 (7.7%)    | 88 (11.0%)      | 0.61 (0.43-0.86) |         |
| del vs ins  |              |                 | 0.78 (0.67-0.91) | 1.24×10⁻³|
| Total effect|              |                 |              |         |
| ins/ins     | 738 (52.7%)  | 639 (45.6%)     | 1.00 (Reference) |         |
| ins/del     | 550 (39.3%)  | 610 (43.6%)     | 0.78 (0.68-0.91) |         |
| del/del     | 112 (8.0%)   | 151 (10.8%)     | 0.64 (0.49-0.84) |         |
| del vs ins  |              |                 | 0.79 (0.70-0.89) | 5.21×10⁻⁴|

aAdjusted by age, gender, alcohol and smoking status
Table 3: Associations between GAS5 rs145204276 and CRC susceptibility stratified by Tumor site

| Genotypes         | Cases (n, %) | Controls (n, %) | OR (95% CI) | P\textsubscript{trend} |
|-------------------|--------------|-----------------|-------------|------------------------|
| Colon             |              |                 |             |                        |
| ins/ins           | 428 (53.1%)  | 639 (45.6%)     | 1.00 (Reference) |                         |
| ins/del           | 313 (38.8%)  | 610 (43.6%)     | 0.77 (0.64-0.92) |                         |
| del/del           | 65 (8.1%)    | 151 (10.8%)     | 0.64 (0.47-0.88) |                         |
| del vs ins        |              |                 | 0.78 (0.68-0.90) | 4.56×10^{-4}            |
| Rectum            |              |                 |             |                        |
| ins/ins           | 310 (52.2%)  | 639 (45.6%)     | 1.00 (Reference) |                         |
| ins/del           | 237 (39.9%)  | 610 (43.6%)     | 0.80 (0.65-0.98) |                         |
| del/del           | 47 (7.9%)    | 151 (10.8%)     | 0.64 (0.45-0.91) |                         |
| del vs ins        |              |                 | 0.80 (0.69-0.93) | 3.80×10^{-3}            |

*adjusted by age, gender, alcohol and smoking status

Table 4: Associations between GAS5 rs145204276 and Lymph node metastasis and Distant metastasis of CRC

| Genotypes         | Event (n, %) | No event (n, %) | OR (95% CI) | P\textsubscript{trend} |
|-------------------|--------------|-----------------|-------------|------------------------|
| Lymph node metastasis |              |                 |             |                        |
| ins/ins           | 286 (56.1%)  | 452 (50.8%)     | 1.00 (Reference) |                         |
| ins/del           | 194 (38.0%)  | 356 (40.0%)     | 0.86 (0.68-1.08) |                         |
| del/del           | 30 (5.9%)    | 82 (9.2%)       | 0.58 (0.37-0.90) |                         |
| del vs ins        |              |                 | 0.80 (0.68-0.95) | 0.010                  |
| Distant metastasis |              |                 |             |                        |
| ins/ins           | 117 (57.1%)  | 621 (52.0%)     | 1.00 (Reference) |                         |
| ins/del           | 78 (38.0%)   | 472 (39.5%)     | 0.88 (0.64-1.20) |                         |
| del/del           | 10 (4.9%)    | 102 (8.5%)      | 0.52 (0.27-1.02) |                         |
| del vs ins        |              |                 | 0.80 (0.63-1.02) | 0.070                  |

*adjusted by age, gender, alcohol and smoking status

Figure 1: Relative expression of GAS5.
divided into 12 exons that span around 7 kb [49]. Then Nakamura et al [50] found that The GAS5 gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. Also GAS5, whose transcript levels were significantly reduced in breast cancer samples relative to adjacent unaffected normal breast epithelial tissues, could control apoptosis and down-regulated in breast cancer [31]. Further literatures reported the potential role of GAS5 in the human T-lymphocytes, renal cell carcinoma, prostate cancer, pancreatic cancer, bladder cancer, non-small-cell lung cancer, gastric cancer, hepatocellular carcinoma, cervical cancer, and so on [27-30, 51-55]. Yin et al [56] found that GAS5 could also affects cell proliferation and predicts a poor prognosis in patients with CRC, although the sample size of recruited patients were limited (only 66 CRC patients).

In current study, we found GAS5 rs145204276 was associated with not only the susceptibility of CRC, but also the lymph node metastasis of CRC. SNP rs145204276 was located in the promoter region of GAS5, and luciferase activity analysis suggested that the deletion allele improved an increased expression of GAS5 [32]. In current study, the statistical power for such an association was 98.1%. Using the online database RegulomeDB (http://regulomedb.org), we found that rs145204276 could bind protein POLR2A, MAX, GATA1, BHLHE40, FOXP2, ATF3, USF2, and so on. While HaploReg v4.1 (http://www.broadinstitute.org/mammals/haploreg/haploreg. php) found that rs145204276 could alter the 9 regulatory motifs, including E2F_disc3, EWSR1-FLI1, MZF1::1-4_3, PTF1-beta, Pbx3_disc3, SP1, STAT, UF1H3BETA, and Znf143.

Conclusively, in this two-stage, case-control study integrating bioinformatics analysis and large-sample size, we highlighted a potential functional locus, GAS5 rs145204276, for susceptibility and progression of CRC. Systematic researches on different population and more susceptibility loci are warranted to identify causal variants and elaborate the genetic etiology for susceptibility and progression of CRC.

MATERIALS AND METHODS

Subjects

This study was a two-stage, case–control sets including 600 newly diagnosed incident CRC cases and 600 healthy controls in stage I, and 800 newly diagnosed incident CRC cases and 800 healthy controls in stage II, which were recruited between 2010 and 2015. All patients had never received any medical treatments, and the diagnosis of patients was validated through pathologic examination by two different senior pathologists. Healthy controls free of any type cancers were selected from health check-up programs at the same hospital during the same period. Then they were matched to the CRC cases by gender and age group, gender, alcohol and smoking status. Then, 5 ml peripheral blood was collected from each subject, and demographic and pathological information were face to face collected by interviewers. The study was approved by appropriate Research Ethics Committee (REC), and written informed consent was obtained from all patients.

Genotyping

Extraction of the genomic DNA from blood samples and HCC tumor tissues was conducted using Qiaqen genomic DNA purification kit. DNA fragments containing the indel polymorphism were amplified using the following genotyping primers: F-TCCCGACTGAGGAGGAAGAGCA; R-AACACC GTCCGGAAGGACCA. The PCR products were analyzed by 7% non-denaturing polyacrylamide gel electrophoresis and visualized by silver staining. Quality control was performed by direct sequencing 5% duplicate samples in blind, with a concordance rate of 100%. Furthermore, a 5% random selected sample was tested in duplicate by different persons, and the concordance rate was 100%.

Statistical analyses

Two-sided Student’s t-test was selected to compare the differences in the quantitative data, while χ2-test was used to analyze the differences of categorical data between the two groups. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were selected to estimate the strength of association between rs145204276 and risk of CRC and its Lymph node metastasis and Distant metastasis by unconditional multivariable logistic regression, adjusted by age group, gender, alcohol and smoking status. HWE of genotypes was evaluated in controls by a goodness-of-fit χ2 test. All statistics were performed using SPSS software 19.0 (SPSS Inc., Chicago, IL, USA), and P values were two sided with the statistical significance criteria of P < 0.05 all through the study.

ACKNOWLEDGMENTS

This study was sponsored by National Natural Science Foundation of China (81372553).

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Bouvier AM, Launoy G. [Epidemiology of colorectal cancer]. Rev Prat. 2015; 65:767-773.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66:7-30.
4. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016.
5. Mitry E, Guiu B, Cosconea S, Jooste V, Faivre J, Bouvier AM. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut. 2010; 59:1383-1388.
6. Ma X, Zhang B, Zheng W. Genetic variants associated with colorectal cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. Gut. 2014; 63:326-336.
7. Li W, Qiu T, Ling Y, Guo L, Li L, Ying J. Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutations. Oncotarget. 2015; 6:39607-39613. doi: 10.18632/oncotarget.5551.
8. Lin J, Qiu M, Xu R, Dobs AS. Comparison of survival and clinicopathologic features in colorectal cancer among African American, Caucasian, and Chinese patients treated in the United States: Results from the surveillance epidemiology and end results (SEER) database. Oncotarget. 2015; 6:33935-33943. doi: 10.18632/oncotarget.5223.
9. Du M, Wang W, Jin H, Wang Q, Ge Y, Lu J, Ma G, Chu H, Tong N, Zhu H, Wang M, Qiang F, Zhang Z. The association analysis of IncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population. Oncotarget. 2015; 6:31255-62. doi: 10.18632/oncotarget.5158.
10. Li H, An J, Wu M, Zheng Q, Gui X, Li T, Pu H, Lu D. LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2. Oncotarget. 2015; 6:27847-64. doi: 10.18632/oncotarget.4443.
11. Li H, Yu B, Li J, Su L, Yan M, Zhu Z, Liu B. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014; 5:2318-2329. doi: 10.18632/oncotarget.1913.
12. Li L, Dang Q, Xie H, Yang Z, He D, Liang L, Song W, Yeh S, Chang C. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population. Oncotarget. 2015; 6:14179-14190. doi: 10.18632/oncotarget.3651. Erratum in: Oncotarget. 2016; 7:83828. doi: 10.18632/oncotarget.13912.
13. Li Y, Chen H, Pan T, Jiang C, Zhao Z, Wang Z, Zhang J, Xu J, Li X. LncRNA ontology: inferring LncRNA functions based on chromatin states and expression patterns. Oncotarget. 2015; 6:39793-39805. doi: 10.18632/oncotarget.5794.
14. Li Y, Chen J, Zhang J, Wang Z, Shao T, Jiang C, Xu J, Li X. Construction and analysis of lncRNA-lncRNA synergetic networks to reveal clinically relevant lncRNAs in cancer. Oncotarget. 2015; 6:25003-25016. doi: 10.18632/oncotarget.4660.
15. Liang WC, Fu WM, Wong CW, Wang Y, Wang WM, Hu GX, Zhang L, Xiao LJ, Wan DC, Zhang JF, Waye MM. The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer. Oncotarget. 2015; 6:22513-22525. doi: 10.18632/oncotarget.4154.
16. Matouk JJ, Halle D, Raveh E, Gilon M, Sorin V, Hochberg A. The role of the oncotelal H19 lncRNA in tumor metastasis: orchestrating the EMT-MET decision. Oncotarget. 2016; 7:3748-3765. doi: 10.18632/oncotarget.6387.
17. Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. lncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer. Oncotarget. 2015; 6:11652-11663. doi: 10.18632/oncotarget.3457.
18. Xue Y, Ma G, Zhang Z, Hua Q, Chu H, Tong N, Yuan L, Qin C, Yin C, Wang M. A novel antisense long noncoding RNA regulates the expression of MDC1 in bladder cancer. Oncotarget. 2015; 6:484-493. doi: 10.18632/oncotarget.2861.
19. Su X, Malouf GG, Chen Y, Zhang J, Yao H, Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, Esteva FJ. Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget. 2014; 5:9864-9876. doi: 10.18632/oncotarget.2454.
20. Wang D, Ding L, Wang L, Zhao Y, Sun Z, Karnes RJ, Zhang J, Huang H. LncRNA MALAT1 enhances oncogenic activities of EZH2 in castration-resistant prostate cancer. Oncotarget. 2015; 6:41045-41055. doi: 10.18632/oncotarget.5728.
21. Wang F, Ying HQ, He BS, Pan YQ, Deng QW, Sun HL, Chen J, Liu X, Wang SK. Uregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway. Oncotarget. 2015; 6:7899-7917. doi: 10.18632/oncotarget.3219.
22. Wang YL, Overstreet AM, Chen MS, Wang J, Zhao HJ, Ho PC, Smith M, Wang SC. Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR. Oncotarget. 2015; 6:11150-11161. doi: 10.18632/oncotarget.3441.
23. Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng J, Xiao W, Yu G, Yao W, Zhou H, Li H, Pan Y, Li A, Ye Z, Wang J, Xu H, et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget. 2015; 6:38005-38015. doi: 10.18632/oncotarget.5357.
24. Pickard MR, Williams GT. The hormone response element mimic sequence of GAS5 lncRNA is sufficient to induce apoptosis in breast cancer cells. Oncotarget. 2016; 7:10104-10116. doi: 10.18632/oncotarget.7173.
25. Han L, Ma P, Liu SM, Zhou X. Circulating long noncoding RNA GAS5 as a potential biomarker in breast cancer for assessing the surgical effects. Tumour Biol. 2016; 37:6847-6854.

26. Liu Y, Zhao J, Zhang W, Gan J, Hu C, Huang G, Zhang Y. IncRNA GAS5 enhances G1 cell cycle arrest via binding to YBX1 to regulate p21 expression in stomach cancer. Scientific reports. 2015; 5:10159.

27. Shi X, Sun M, Liu H, Yao Y, Kong R, Chen F, Song Y. A critical role for the long non-coding RNA GAS5 in proliferation and apoptosis in non-small-cell lung cancer. Mol Carcinogen. 2015; 54 Suppl 1:E1-E12.

28. Liu Z, Wang W, Jiang J, Bao E, Xu D, Zeng Y, Tao L, Qiu J. Downregulation of GAS5 promotes bladder cancer cell proliferation, partly by regulating CDK6. PLoS One. 2013; 8:e73991.

29. Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X, Chen H, Jin J, Peng C, Li H, Shen B. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating by CDK6. Cell and tissue research. 2013; 354:891-896.

30. Pickard MR, Mourtada-Maarabouni M, Williams GT. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim Biophys Acta. 2013; 1832:1613-1623.

31. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT. GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2009; 28:195-208.

32. Tao R, Hu S, Wang S, Zhou X, Zhang Q, Wang C, Zhao X, Zhou W, Zhang S, Li C, Zhao H, He Y, Zhu S, Xu J, Jiang Y, Li L, et al. Association between indel polymorphism in the promoter region of IncRNA GAS5 and the risk of hepatocellular carcinoma. Carcinogenesis. 2015; 36:1136-1143.

33. Wang F, Ni H, Sun F, Li M, Chen L. Overexpression of IncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016; 81:152-159.

34. Chen D, Sun Q, Cheng X, Zhang L, Song W, Zhou D, Lin J, Wang W. Genome-wide analysis of long noncoding RNA (IncRNA) expression in colorectal cancer tissues from patients with liver metastasis. Cancer medicine. 2016; 5:1629-1639.

35. Dou J, Ni Y, He X, Wu D, Li M, Wu S, Zhang R, Guo M, Zhao F. Decreasing IncRNA HOTAIR expression inhibits human colorectal cancer stem cells. Am J Transl Res. 2016; 8:98-108.

36. Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, Feng Y, Liu H, Fei B, Mao Y, Zhou L, Qi X, Huang S, Hua D, Xing C, Huang Z. LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p. Scientific reports. 2016; 6:23892.

37. Li S, Hua Y, Jin J, Wang H, Du M, Zhu L, Chu H, Zhang Z, Wang M. Association of genetic variants in IncRNA H19 with risk of colorectal cancer in a Chinese population. Oncotarget. 2016; 7:25470-7. doi: 10.18632/oncotarget.8330.

38. Sun L, Xue H, Jiang C, Zhou H, Gu L, Liu Y, Xu C, Xu Q. LncRNA DQ786243 contributes to proliferation and metastasis of colorectal cancer both in vitro and in vivo. Bioscience reports. 2016; 36.

39. Liu Y, Zhang M, Liang L, Li J, Chen YX. Over-expression of IncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer. International journal of clinical and experimental pathology. 2015; 8:11480-11484.

40. Liao Q, He W, Liu J, Cen Y, Luo L, Yu C, Li Y, Chen S, Duan S. Identification and functional annotation of IncRNA genes with hypermethylation in colorectal cancer. Gene. 2015; 572:259-265.

41. Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of IncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015; 8:3707-3715.

42. Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, Ueda M, Sakimura S, Takano Y, Kurashige J, Shindend Y, Eguchi H, Sugimachi K, Maehara Y, Mimori K. A long noncoding RNA, IncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Res. 2015; 35:1385-1388.

43. Xue Y, Gu D, Ma G, Zhu L, Hua Q, Chu H, Tong N, Chen J, Zhang Z, Wang M. Genetic variants in IncRNA HOTAIR are associated with risk of colorectal cancer. Mutagenesis. 2015; 30:303-310.

44. Zheng HT, Shi DB, Wang YW, Li XX, Xu Y, Tripathi P, Gu WL, Cai GX, Cai SJ. High expression of IncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. International journal of clinical and experimental pathology. 2014; 7:3174-3181.

45. Shi D, Zheng H, Zhuo C, Peng J, Li D, Xu Y, Li X, Cai G, Cai S. Low expression of novel IncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer. Med Oncol. 2014; 31:31.

46. Xiang JF, Yin QF, Chen T, Zhang Y, Zhang XO, Wu Z, Zhang S, Wang HB, Ge J, Lu X, Yang L, Chen LL. Human colorectal cancer-specific CCAT1-L IncRNA regulates long-range chromatin interactions at the MYC locus. Cell Res. 2014; 24:513-531.

47. Shi J, Li X, Zhang F, Zhang C, Guan Q, Cao X, Zhu W, Zhang X, Cheng Y, Ou K, Chen Q, Hu S. Circulating lncRNAs associated with occurrence of colorectal cancer progression. American journal of cancer research. 2015; 5:2258-2265.

48. Han J, Rong LF, Shi CB, Dong XG, Wang J, Wang BL, Wen H, He ZY. Screening of lymph nodes metastasis...
associated lncRNAs in colorectal cancer patients. World J Gastroenterol. 2014; 20:8139-8150.

49. Coccia EM, Cicala C, Charlesworth A, Ciccarelli C, Rossi GB, Philipson L, Sorrentino V. Regulation and expression of a growth arrest-specific gene (gas5) during growth, differentiation, and development. Mol Cell Biol. 1992; 12:3514-3521.

50. Nakamura Y, Takahashi N, Kakegawa E, Yoshida K, Ito Y, Kayano H, Niitsu N, Jinnai I, Bessho M. The GAS5 (growth arrest-specific transcript 5) gene fuses to BCL6 as a result of t(1;3)(q25;q27) in a patient with B-cell lymphoma. Cancer Genet Cytogenet. 2008; 182:144-149.

51. Williams GT, Mourtada-Maarabouni M, Farzaneh F. A critical role for non-coding RNA GAS5 in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochem Soc Trans. 2011; 39:482-486.

52. Qiao HP, Gao WS, Huo JX, Yang ZS. Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pac J Cancer Prev. 2013; 14:1077-1082.

53. Cao S, Liu W, Li F, Zhao W, Qin C. Decreased expression of IncRNA GAS5 predicts a poor prognosis in cervical cancer. International journal of clinical and experimental pathology. 2014; 7:6776-6783.

54. Tu ZQ, Li RJ, Mei JZ, Li XH. Down-regulation of long non-coding RNA GAS5 is associated with the prognosis of hepatocellular carcinoma. International journal of clinical and experimental pathology. 2014; 7:4303-4309.

55. Sun M, Jin FY, Xia R, Kong R, Li JH, Xu TP, Liu YW, Zhang EB, Liu XH, De W. Decreased expression of long noncoding RNA GAS5 indicates a poor prognosis and promotes cell proliferation in gastric cancer. BMC Cancer. 2014; 14:319.

56. Yin D, He X, Zhang E, Kong R, De W, Zhang Z. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer. Med Oncol. 2014; 31:253.